Your browser doesn't support javascript.
loading
Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration.
Awh, Katherine C; Mahmoudzadeh, Raziyeh; Salabati, Mirataollah; Mansour, Hana A; Bechay, Joseph; Magagna, John; Regillo, Carl D; Ho, Allen C; Garg, Sunir J; Hsu, Jason.
Afiliación
  • Awh KC; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania.
  • Mahmoudzadeh R; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Salabati M; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Mansour HA; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Bechay J; Department of Ophthalmology, The George Washington University School of Medicine and Health Sciences (J.B.), Washington, District of Columbia, USA.
  • Magagna J; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania.
  • Regillo CD; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Ho AC; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Garg SJ; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania.
  • Hsu J; From the Sidney Kimmel Medical College, Thomas Jefferson University (K.C.A., J.M., J.H.), Philadelphia, Pennsylvania; The Retina Service of Wills Eye Hospital, Wills Eye Physicians-Mid Atlantic Retina (R.M., M.S., H.A.M., C.D.R., A.C.H., S.J.G., J.H.), Philadelphia, Pennsylvania. Electronic address:
Am J Ophthalmol ; 256: 20-26, 2023 12.
Article en En | MEDLINE | ID: mdl-37517527
PURPOSE: To determine the outcomes of intentionally suspending anti-vascular endothelial growth factor (anti-VEGF) injections in eyes with advanced neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective cohort study. METHODS: The study sample comprised 93 patients with nAMD and best available Snellen visual acuity (VA) ≤20/400 in which anti-VEGF treatment was suspended by the treating physician. VA and optical coherence tomography (OCT) characteristics were evaluated to determine visual and anatomical outcomes up to 24 months after treatment suspension. RESULTS: A total of 93 eyes from 93 patients who had received a mean of 16 anti-VEGF injections over a mean of 962 (SD 562) days were included. Comparing the treatment suspension visit to 24 months later, no significant change in mean central foveal thickness (163 [SD 118, range 19-704] µm vs 164 [SD 217, range 19-1468], P = .97), greatest lesion diameter (2547 [SD 1294, range 134-5707] µm vs 2442 [SD 1158, range 421-5305] µm, P = .43), greatest lesion thickness (194 [SD 136, range 0-618] µm vs 205 [SD 131, range 0-573] µm, P = .40), or VA (1.87 [SD 0.37], 20/1482, vs 1.94 [SD 0.28], 20/1741, P = .16) was found. In total, 7 eyes (7.5%) restarted treatment following a mean of 977 (SD 450) days after treatment suspension. CONCLUSIONS: Suspension of anti-VEGF injections in eyes with advanced nAMD and VA ≤20/400 may be reasonable in cases where the treating physician deems additional treatment is unlikely to provide benefit. Although the visual and anatomical findings remained stable after treatment suspension in most, a small number restarted anti-VEGF therapy, suggesting that eyes should still be monitored for disease progression.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Degeneración Macular Húmeda / Degeneración Macular Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Am J Ophthalmol Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Degeneración Macular Húmeda / Degeneración Macular Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Am J Ophthalmol Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos